Prognostic Nutritional Index as a Prognostic Indicator for the Occurrence of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy

References

• Zhang Y. Epidemiology of esophageal cancer. World J Gastroenterol. 2013;19(34):5598. doi:10.3748/wjg.v19.i34.5598
   PubMed Web of Science ®Google Scholar
• Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–412.
   PubMed Web of Science ®Google Scholar
• Wu C, Li M, Meng H, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62(5):640–647. doi:10.1007/s11427-018-9461-5
   PubMed Web of Science ®Google Scholar
• Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v50–v7. doi:10.1093/annonc/mdw329
   PubMed Web of Science ®Google Scholar
• Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon geka gakkai zasshi. 1984;85(9):1001–1005.
   PubMedGoogle Scholar
• Buzby GP, Mullen JL, Matthews DC, Hobbs CL, Rosato EF. Prognostic nutritional index in gastrointestinal surgery. Am J Surg. 1980;139(1):160–167. doi:10.1016/0002-9610(80)90246-9
   PubMed Web of Science ®Google Scholar
• Hirahara N, Tajima Y, Fujii Y, et al. Preoperative prognostic nutritional index predicts long-term surgical outcomes in patients with esophageal squamous cell carcinoma. World J Surg. 2018;42(7):2199–2208. doi:10.1007/s00268-017-4437-1
   PubMed Web of Science ®Google Scholar
• Feng J-F, Chen Q-X. Significance of the prognostic nutritional index in patients with esophageal squamous cell carcinoma. Therap Clin Risk Manage. 2013;1–7. doi:10.2147/TCRM.S56159
   PubMed Web of Science ®Google Scholar
• Koppie TM, Serio AM, Vickers AJ, et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer. 2008;112(11):2384–2392. doi:10.1002/cncr.23462
   PubMed Web of Science ®Google Scholar
• Rice TW, Ishwaran H, Ferguson MK, Blackstone EH, Goldstraw P. Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncol. 2017;12(1):36–42.
   PubMed Web of Science ®Google Scholar
• Liu Y, Bao Y, Yang X, et al. Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: a systematic review and meta-analysis. Front Immunol. 2023;14:1117448. doi:10.3389/fimmu.2023.1117448
   PubMed Web of Science ®Google Scholar
• Shen D, Chen Q, Wu J, Li J, Tao K, Jiang Y. The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma. J Gastrointest Oncol. 2021;12(1):1. doi:10.21037/jgo-20-599
   PubMed Web of Science ®Google Scholar
• Yang P, Zhou X, Yang X, et al. Neoadjuvant camrelizumab plus chemotherapy in treating locally advanced esophageal squamous cell carcinoma patients: a pilot study. World J Surg Oncol. 2021;19(1):1–8. doi:10.1186/s12957-021-02446-5
   PubMed Web of Science ®Google Scholar
• Duan H, Shao C, Pan M, et al. Neoadjuvant pembrolizumab and chemotherapy in resectable esophageal cancer: an open-label, single-arm study (PEN-ICE). Front Immunol. 2022;13:849984. doi:10.3389/fimmu.2022.849984
   PubMed Web of Science ®Google Scholar
• Liu J, Li J, Lin W, et al. Neoadjuvant camrelizumab plus chemotherapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC‐ESCC2019): a multicenter, Phase 2 study. Int J Cancer. 2022;151(1):128–137. doi:10.1002/ijc.33976
   PubMed Web of Science ®Google Scholar
• Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, Phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. Journal for Immunotherapy of Cancer. 2022;10(3):e004291. doi:10.1136/jitc-2021-004291
   PubMed Web of Science ®Google Scholar
• Lv H, Tian Y, Li Z, Huang C, Xu Y, Tian Z. 557 neoadjuvant camrelizumab in combination with albumin paclitaxel and cisplatin for patients with locally advanced esophageal squamous cell carcinoma (ESCC). BMJ Spec J. 2021;3:1.
   Google Scholar
• Wang J, Zhang K, Liu T, et al. Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: a meta-analysis. Front Oncol. 2022;12:974684. doi:10.3389/fonc.2022.974684
   PubMedGoogle Scholar
• Wu Z, Zheng Q, Chen H, et al. Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. J Thoracic Dis. 2021;13(6):3518. doi:10.21037/jtd-21-340
   PubMed Web of Science ®Google Scholar
• Lv H, Tian Y, Li J, et al. Neoadjuvant sintilimab plus chemotherapy in resectable locally advanced esophageal squamous cell carcinoma. Front Oncol. 2022;12:864533.
   PubMedGoogle Scholar
• Xu W, Jiang Y, Wang C, et al. The efficacy and safety of neoadjuvant camrelizumab and chemotherapy for locally advanced thoracic esophageal squamous cell carcinoma. Am Soc Clin Oncol. 2022;5:1.
   Google Scholar
• Li P, Wang X, Lai Y, Zhou K, Tang Y, Che G. The prognostic value of pre-treatment prognostic nutritional index in esophageal squamous cell carcinoma: a meta-analysis. Medicine. 2019;98:22.
   Web of Science ®Google Scholar
• Hao J, Chen C, Wan F, et al. Prognostic value of pre-treatment prognostic nutritional index in esophageal cancer: a systematic review and meta-analysis. Front Oncol. 2020;3:10.
   Google Scholar
• Qi Q, Song Q, Cheng Y, Wang N. Prognostic significance of preoperative prognostic nutritional index for overall survival and postoperative complications in esophageal cancer patients. Cancer Manage Res. 2021;13:8585–8597. doi:10.2147/CMAR.S333190
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang L, Fang M, et al. Prognostic value of the geriatric nutritional risk index in patients exceeding 70 years old with esophageal squamous cell carcinoma. Nutr Cancer. 2020;72(4):620–626. doi:10.1080/01635581.2019.1650189
   PubMed Web of Science ®Google Scholar
• Toyokawa T, Kubo N, Tamura T, et al. The pretreatment Controlling Nutritional Status (CONUT) score is an independent prognostic factor in patients with resectable thoracic esophageal squamous cell carcinoma: results from a retrospective study. BMC Cancer. 2016;16(1):1–11. doi:10.1186/s12885-016-2696-0
   Google Scholar